ALLERGOVIT®

Fast and long-lasting effect[1–4,*,**]

ALLERGOVIT® is a hypoallergenic, high-dose[5] preparation (allergoid) for subcutaneous allergen immunotherapy (SCIT) in pollen allergies. ALLERGOVIT® is available in several dosage regimens, depending on the therapy preferences you have agreed with your patient. You have a choice between a longer escalation scheme of 7 injections[6] for highly sensitized patients, or a shorter scheme of 4 injections[6] (adult patients allergic to grasses, cereals and/or fagales pollen). You also have the option to escalate with strength B exclusively[6] (children, adolescents and adults allergic to grass and cereal pollen). During maintenance treatment, ALLERGOVIT® offers a maximum of flexibility with injection intervals of 4 to 8 weeks[6]. The treatment has a proven efficacy in the first pollen season[1,2,*] as well as 15 years of long-term effect[3,4,**]. ALLERGOVIT® is one of the most widely used pollen-preparations for allergen immunotherapy.

✓ **Rapid effect**
from the first pollen season[1,2,*]

✓ **Long-term effect**
for up to 15 years[3,4,**]

✓ **Well-tolerated**
in clinical and everyday practice[6,7]

Allergen sources available for the therapy of pollen allergies

Single allergen sources

ALLERGOVIT®

Grasses/cereals

006	Grasses	100 %
133	Velvet grass	in equal parts
140	Orchard grass	
157	Rye grass	
177	Timothy grass	
178	Kentucky blue grass	
179	Meadow fescue	

Tree

108	Birch	100 %
151	Olive tree	100 %

Weeds

106	Mugwort	100 %
123	Wall pellitory	100 %
154	Short ragweed	100 %
169	English plantain	100 %

Mixtures

ALLERGOVIT®

015	Grasses/cereals	100 %
006	Grasses	55 %
121	Barley	10 %
126	Oat	10 %
158	Rye	15 %
173	Wheat	10 %

006	Grasses	60 %
158	Rye	40 %

006	Grasses	60 %
108	Birch	20 %
158	Rye	20 %

006	Grasses	60 %
106	Mugwort, common	20 %
158	Rye	20 %

006	Grasses	60 %
158	Rye	20 %
169	English plantain	20 %

Mixtures

ALLERGOVIT®

108	Birch	35 %
115	Alder	30 %
121	Hazel	35 %

115	Alder	50 %
121	Hazel	50 %

006	Grasses	50 %
151	Olive tree	50 %

108	Birch	50 %
151	Olive tree	50 %

* With Allergovit® grasses and Allergovit® birch; refers to the combined symptom-medication score. ** In adults, the reduction in the symptom-medication score was retained 6 years after termination of AIT with Allergovit® grasses. In children, symptoms and use of medication were still reduced 12 years after termination of AIT with Allergovit® grasses compared to a control group.

allergopharma

ALLERGOVIT®

Fast and long-lasting effect[1-4,*,**]

ALLERGOVIT®

Dosage recommendations

Strength A Strength B

One-strength dose escalation scheme

with all ALLERGOVIT® grass and cereal pollen preparations for all age groups (children, adolescents and adults)[6]



Accelerated dose escalation scheme

with ALLERGOVIT® grass, cereal and fagales pollen preparations for adults[6]



Standard dose escalation scheme

with all ALLERGOVIT® pollen preparations for all age groups (children, adolescents and adults)[6]



Dose modification in case of interval exceedance[6]

Introductory treatment

Interval since the last injection	Dosage modification
> 2 weeks	Dose reduction by one level
> 4 weeks	New start

Maintenance treatment

Interval since the last injection	Dosage modification
> 8 weeks	Dose reduction by one level
> 9 weeks	New start

Introductory treatment

Strengths AB

Strengths ABB

Maintenance treatment#

1x Strength B

2x Strength B

Strength A: 1000 TU/mL, Strength B: 10 000 TU/mL. The standardization is measured in TU (therapeutic units).

^ The dosage is decided on the basis of the patient's tolerance. ^^ Pre-seasonal: Continuation treatment until approx. 1 week before the start of the pollen season. Perennial: Observe dose reduction during pollen season. Not required with ALLERGOVIT® for tree pollen, grass pollen and cereal pollen in adults. For further information, please see summary of product characteristics or basic information (page 3)

* With Allergovit® grasses and Allergovit® birch; refers to the combined symptom-medication score. ** In adults, the reduction in the symptom-medication score was retained 6 years after termination of AIT with Allergovit® grasses. In children, symptoms and use of medication were still reduced 12 years after termination of AIT with Allergovit® grasses compared to a control group.

Strength B may be used for maintenance treatment or for introductory treatment if one-strength dose escalation scheme is used.

allergopharma

ALLERGOVIT®

Note

This information about Allergopharma products, dosage recommendations and the availability of allergen sources may vary from country to country. For specific information, please contact your local distributor.

ALLERGOVIT® POLLEN PREPARATION

Composition: Chemically modified allergen extracts (allergoids) from pollen for allergen immunotherapy / hyposensitization, adsorbed to aluminium hydroxide, preserved with phenol and suspended in physiological saline solution with sodium hydrogen carbonate; water for injection. Standardization is indicated in TU (therapeutic units). Strength A: 1 000 TU/mL; strength B: 10 000 TU/mL.

Indications: Causal treatment of allergic (IgE-mediated) diseases, such as allergic rhinitis, allergic conjunctivitis, allergic bronchial asthma etc., triggered by exposure to unavoidable allergens.

Contraindications: Hypersensitivity to any of the excipients, uncontrolled asthma, irreversible changes in the reaction organ, inflammatory/febrile diseases, severe acute or chronic diseases (e.g. malignant diseases, active tuberculosis), clinically significant cardiovascular insufficiency - in cardiovascular diseases, there is an increased risk of adverse reactions to adrenaline, treatment with beta-blockers (local, systemic), diseases of the immune system (autoimmune diseases, immune complex-induced immunopathies, immunodeficiencies, multiple sclerosis etc.), severe mental disorders.

Side effects: Local and/or systemic reactions (up to anaphylactic shock) must be expected, then stop injection immediately. Hypersensitivity; anaphylactic reaction; anaphylactic shock; drug intolerance; conjunctival oedema; conjunctival disorder; conjunctivitis (allergic); eye pruritus; eye irritation; mydriasis; visual impairment; conjunctival hyperaemia; ocular hyperaemia; swelling of eyelid; eyelid oedema; face oedema; angioedema; oral pruritus; swollen tongue; lip swelling; laryngeal oedema; glossodynia; dysphagia; gastrointestinal disorder; abdominal pain; nausea; diarrhoea; vomiting; increased appetite; weight increased; salivary hypersecretion; at the injection site: erythema, pruritus, swelling, pain, discolouration, reaction, rash, urticaria, warmth, discomfort, eczema, erosion, granuloma, nodule, haematoma, haemorrhage, hypersensitivity, hypoaesthesia, induration, oedema, vesicles, cellulitis, paraesthesia, scar; local reaction; malaise; asthenia; discomfort; paraesthesia; inflammation; pyrexia; feeling hot; feeling of body temperature change; chills; hyperhidrosis; headache; migraine; dizziness; vertigo; tachycardia; palpitations; chest discomfort; loss of consciousness; syncope; cold sweat; anxiety; restlessness; tiredness; somnolence; insomnia; sensation of foreign body; flushing; burning sensation; tremor; pain; flank pain; pain in extremity; arthralgia; swelling; peripheral swelling; oedema peripheral; nasopharyngitis; rhinitis (allergic); nasal pruritus; nasal congestion; oropharyngeal pain; rhinorrhoea; increased upper airway secretion; asthma; asthmatic crisis; bronchospasm; tachypnoea; respiratory distress; cough; pseudocroup; dyspnoea; cyanosis; sneezing; throat irritation; throat tightness; stridor; wheezing; forced expiratory volume decreased; peak expiratory flow rate decreased; blood pressure diastolic increased; blood pressure systolic increased; blood pressure decreased; orthostatic hypotension; urinary incontinence; dermatitis atopic; dermatitis allergic; neurodermatitis; scleroderma; (generalized) erythema; granuloma skin; blister; pruritus (generalized); rash (generalized); urticaria (chronic); eczema; haematoma; lymphoedema. When using the dosage scheme with an accelerated dose increase (4 injections, only for adults, grass and cereal pollen and tree pollen), side effects can occur more frequently than with the escalation treatment according to the standard scheme. The side effects mostly only appear 30 minutes after the injection. The systemic reactions are mild and not more pronounced in severity than in the standard scheme. When using the one-strength dose escalation scheme (3 injections, only for grass and cereal pollen), side effects can occur more frequently than when using the standard scheme. In addition, these occur at an earlier time in the dose escalation phase compared to the standard scheme. The severity of the systemic reactions is not more pronounced than in the standard scheme.

For additional information on doses, administration etc. see package insert. The general classification for supply depends on local requirements.

Date of information: May 2020

References

1. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium adsorbed six-grass pollen allergoid. Allergy 2005; 60: 801–7.
2. Wagenmann M, Worm M, Akboga Y, Karjalainen M, Hohlfeld JM. Randomized immunotherapy trial in dual allergic patients using "active allergen placebo" as control. Allergy 2019;74:1480–9.
3. Kettner J, Mussler S, Häfner D, Narkus A. Considerable 6 years post treatment long-term effect of pre-seasonal subcutaneous specific immunotherapy (SCIT) with a high-dose hypoallergenic grass pollen preparation. Allergy 2011;66[S94]:296.
4. Eng PA, Borer-Reinhold M, Heijnen IAFM, Gnehm HPE. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006;61:198-201.
5. Brehler R, Kahlert H, Thum-Oltmer S. Hypoallergenic preparations in SCIT. Immunological features and their impact on clinical efficacy and safety, exemplary for the allergoids ALLERGOVIT®, ACAROID® and a folding variant of the recombinant birch pollen major allergen Bet v 1. Allergo J 2010; 19: 477–84.
6. SUMMARY OF PRODUCT CHARACTERISTICS: ALLERGOVIT® Pollen preparations Version-2a-INT from 05/2020
7. Hoheisel G, Martin E, Jaeschke B, Thum-Oltmer S. Hypoallergenic high-dose immunotherapy proves effective and safe in a multicentre surveillance study. Allergo J 2012; 21: 294–301.

Distributors

AUSTRIA

Allergopharma Vertriebsges. mbH
Kleeblattgasse 4/13
1010 Wien
Phone +43 1 61571540
Fax +43 1 6157153
Email office.at@allergopharma.com
Web www.allergopharma.at

CHINA

Allergopharma (Beijing)
Pharmaceutical Technology Co., Ltd.
Room 19, 2nd Floor, Building #8,/Number 1,
Baohui Street, Shunyi District
101300 Beijing
Phone +86 10 6475 8287
Email inquiry-safety@allergopharma.cn

GERMANY (HEADQUARTERS)

Allergopharma GmbH & Co. KG
Hermann-Körner-Straße 52
21465 Reinbek
Phone +49 40 72765 0
Fax +49 40 7227713
Email info@allergopharma.com
Web www.allergopharma.de
www.allergopharma.com

LUXEMBOURG

CPL S.A.
16, rue de l'Industrie
3895 Foetz
Phone +35 2 55 60 66 1
Fax +35 2 55 60 66 250
Email administration@cplux.lu
Web online.cplux.lu

POLAND

SUN-FARM Sp. z o.o.
ul. Dolna 21
05-092 Łomianki
Phone +48 22 350 66 69
Fax +48 22 350 77 03
Email biuro@sunfarm.pl
Web www.sunfarm.pl

SOUTH KOREA

Allerpha International
2202, 37, Gukjegeumyung-ro 2-gil
Yeongdeungpo-gu
07327 Seoul
Phone +82 27803928
Fax +82 27864991
Email allerpha@allerpha.com
Web www.allerpha.com

SPAIN

Allergopharma Espana S.L.
C/ Amaltea 9, 4ª planta, letra B
28045 Madrid
Phone +34 91 076 18 78
Email consultas.es@allergopharma.com
Web www.allergopharma.es

SWITZERLAND

Allergopharma / Dermapharm AG
Bösch 104
6331 Hünenberg
Phone +41 61 721 88 66
Fax +41 61 721 88 68
Email info@allergopharma.ch
Web www.allergopharma.ch

TURKEY

Allergo Ilac Dis Ticaret A.S.
Fahrettin Kerim Gökay Cad. Ak Apt.
No. 144 K.1 D. 3
34724 Göztepe / Istanbul
Phone +90 2165651300
Email info@allergo.com.tr
Web www.allergo.com.tr

UNITED KINGDOM

Diagenics Ltd.
Bond Avenue Bletchley Office 2
Milton Keynes MK1 1SW
Phone +44 1908 376376
Fax +44 1908 376375
Email info@diagenics.co.uk
Web www.diagenics.co.uk

Allergopharma GmbH & Co. KG
Hermann-Körner-Str. 52 • 21465 Reinbek • Germany
Tel. +49 40 727 65-0 • Fax +49 40 722 7713
info@allergopharma.com • www.allergopharma.com

Allergen Immunotherapy Made in Germany

allergopharma